FDA Advisory Committee to Review Lykos Therapeutics’ MDMA-Assisted Therapy in Early June – Psychedelic Alpha

Save the date: the FDA will hold an advisory committee meeting to review Lykos Therapeutics’ New Drug Application (NDA) for MDMA-assisted psychotherapy in the treatment of PTSD on June 4th, 2024.

The purpose of FDA advisory committees is to provide “independent, expert advice” to the agency [1]. In this case, it will be the agency’s Psychopharmacologic Drugs Advisory Committee (PDAC) that is tasked with reviewing Lykos’ data package and considering how the investigational treatment might be used in practice.

Sign in or Join to continue reading…

This article is exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.

Cano Health Emerges from Chapter 11, Focused on Florida Market

What You Should Know: – Cano Health, a value-based primary care provider, announced today that it has successfully exited Chapter 11 bankruptcy as a reorganized

July 3, 2024

Black women weigh emerging risks of ‘creamy crack’ hair straighteners

Deanna Denham Hughes was stunned when she was diagnosed with ovarian cancer last year. She was only 32. She had no family history of cancer,

August 1, 2023

Study discovers epigenetic regulator’s critical role in mitochondrial metabolism

The intricate control of cellular metabolism relies on the coordinated and harmonious interplay between the nucleus and mitochondria.

October 10, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.